MY125399A - Benzimidazole compound crystal. - Google Patents

Benzimidazole compound crystal.

Info

Publication number
MY125399A
MY125399A MYPI20002497A MY125399A MY 125399 A MY125399 A MY 125399A MY PI20002497 A MYPI20002497 A MY PI20002497A MY 125399 A MY125399 A MY 125399A
Authority
MY
Malaysia
Prior art keywords
compound crystal
benzimidazole compound
methyl
benzimidazole
crystal
Prior art date
Application number
Other languages
English (en)
Inventor
Fujishima Akira
Aoki Isao
Kamiyama Keiji
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15924444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY125399(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MY125399A publication Critical patent/MY125399A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI20002497 1999-06-17 2000-06-02 Benzimidazole compound crystal. MY125399A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17150999 1999-06-17

Publications (1)

Publication Number Publication Date
MY125399A true MY125399A (en) 2006-07-31

Family

ID=15924444

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20002497 MY125399A (en) 1999-06-17 2000-06-02 Benzimidazole compound crystal.

Country Status (26)

Country Link
US (11) US6462058B1 (forum.php)
EP (3) EP2343289A1 (forum.php)
KR (3) KR100407847B1 (forum.php)
CN (1) CN1150186C (forum.php)
AR (5) AR031069A1 (forum.php)
AT (1) ATE391126T1 (forum.php)
AU (1) AU778820B2 (forum.php)
BE (1) BE2014C017I2 (forum.php)
BR (1) BRPI0011674B8 (forum.php)
CA (1) CA2375201C (forum.php)
CY (2) CY1110384T1 (forum.php)
DE (1) DE60038481T2 (forum.php)
DK (2) DK1977751T3 (forum.php)
ES (2) ES2426985T3 (forum.php)
HU (1) HU229067B1 (forum.php)
IL (2) IL145996A0 (forum.php)
MX (1) MXPA01012642A (forum.php)
MY (1) MY125399A (forum.php)
NO (1) NO321168B1 (forum.php)
NZ (1) NZ515702A (forum.php)
PL (1) PL201068B1 (forum.php)
PT (2) PT1977751E (forum.php)
SI (1) SI1129088T1 (forum.php)
TW (2) TWI289557B (forum.php)
WO (2) WO2000078745A2 (forum.php)
ZA (1) ZA200108331B (forum.php)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20040224989A1 (en) * 1999-01-29 2004-11-11 Barberich Timothy J. S-lansoprazole compositions and methods
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
WO2001002389A1 (fr) * 1999-06-30 2001-01-11 Takeda Chemical Industries, Ltd. Cristaux de composes benzimidazole
AU2001252595A1 (en) 2000-04-28 2001-11-12 Takeda Chemical Industries Ltd. Process for producing optically active sulfoxide derivative
CA2701704C (en) * 2000-05-15 2011-09-06 Takeda Pharmaceutical Company Limited Process for producing crystal
CA2775616C (en) 2000-08-04 2013-09-17 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and application thereof
CA2436825C (en) * 2000-12-01 2011-01-18 Takeda Chemical Industries, Ltd. Process for the crystallization of (r)- or (s)-lansoprazole
DK1459737T3 (da) 2001-10-17 2013-01-02 Takeda Pharmaceutical Granulat indeholdende syreustabilt kemisk middel i stor mængde
KR100467100B1 (ko) * 2002-03-20 2005-01-24 일양약품주식회사 2-[(4-메톡시-3-메틸)-2-피리디닐]메틸설피닐-5-(1Ｈ-피롤-1-릴)-1Ｈ-벤즈이미다졸 또는 이의 Ｎа염을 함유하는주사제의 제조방법
PL373539A1 (en) * 2002-03-27 2005-09-05 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP2596792A1 (en) * 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Stable solid preparations
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
CA2516600C (en) 2003-03-24 2011-04-05 Eisai Co., Ltd. Process for production of sulfoxide proton pump inhibitors in the amorphous state
CA2529255A1 (en) * 2003-06-20 2004-12-29 Ch Chemicals (Pty) Ltd Polyurethane-based cementitious liner
EP1648416A4 (en) * 2003-07-18 2012-03-28 Santarus Inc PHARMACEUTICAL FORMULATIONS FOR INHIBITING THE ACIDIC ACIDIFICATION AND MANUFACTURING AND USE METHOD
MXPA06000524A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulacion farmaceutica y metodo para tratar desordenes gastrointestinales provocados por acido.
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
WO2005117870A2 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2570916C (en) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
EP2264025B1 (en) 2004-09-13 2013-11-06 Takeda Pharmaceutical Company Limited Method for producing lansoprazole
ES2675581T3 (es) 2005-02-25 2018-07-11 Takeda Pharmaceutical Company Limited Método para producir gránulos de un compuesto de bencimidazol recubiertos
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
BRPI0617987A2 (pt) * 2005-10-06 2011-08-16 Auspex Pharmaceuticals Inc composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico
KR20080081071A (ko) 2005-12-28 2008-09-05 다케다 야쿠힌 고교 가부시키가이샤 방출 제어 고형 제제
KR100758600B1 (ko) 2006-01-05 2007-09-13 주식회사 대웅제약 란소프라졸 결정형 ａ의 제조방법
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20100093804A1 (en) * 2006-12-07 2010-04-15 Hetero Drugs Limited novel crystalline form of lansoprazole
JP5366558B2 (ja) 2006-12-28 2013-12-11 武田薬品工業株式会社 口腔内崩壊性固形製剤
CN104069088A (zh) * 2007-10-12 2014-10-01 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
NZ593629A (en) * 2007-12-18 2012-11-30 Watson Pharma Private Ltd Stable amorphous R-lansoprazole prepared by optically resolving racemic lansoprazole
EP2292612A3 (en) * 2007-12-31 2011-05-04 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
AR070972A1 (es) * 2008-03-10 2010-05-19 Takeda Pharmaceutical Cristal de compuestos de bencimidazol (lansoprazol)
NZ588407A (en) * 2008-03-11 2012-07-27 Takeda Pharmaceutical Orally-disintegrating solid preparation
WO2009117489A1 (en) * 2008-03-18 2009-09-24 Dr. Reddy's Laboratories Ltd. Dexlansoprazole process and polymorphs
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
WO2010079504A2 (en) 2008-05-14 2010-07-15 Watson Pharma Private Limited Stable r(+)-lansoprazole amine salt and a process for preparing the same
EP2309985B1 (en) * 2008-07-28 2018-03-14 Takeda Pharmaceutical Company Limited Pharmaceutical composition
WO2010039885A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
IT1391758B1 (it) * 2008-11-11 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo amorfo
WO2010056059A2 (en) * 2008-11-14 2010-05-20 Hanmi Pharm. Co., Ltd. Novel crystalline dexlansoprazole and pharmaceutical composition comprising same
IT1391776B1 (it) * 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
IT1392813B1 (it) 2009-02-06 2012-03-23 Dipharma Francis Srl Forme cristalline di dexlansoprazolo
US20110009637A1 (en) * 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011004387A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
IT1395118B1 (it) * 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
CN108383804A (zh) 2009-11-12 2018-08-10 特罗菲克斯制药股份有限公司 神经营养蛋白模拟化合物及其盐的晶型
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
CN102108076B (zh) * 2009-12-23 2014-07-23 江苏豪森医药集团有限公司 制备无定形右兰索拉唑的方法
AU2011210328A1 (en) 2010-01-29 2012-08-16 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
AU2011234003B2 (en) * 2010-03-31 2013-09-19 Sun Pharmaceutical Industries Limited Process for the preparation of dexlansoprazole
WO2011121546A1 (en) 2010-03-31 2011-10-06 Ranbaxy Laboratories Limited Salts of dexlansoprazole and their preparation
EP2384747A3 (en) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Oral Tablet Compositions Of Dexlansoprazole
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
EP2384745A3 (en) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release pharmaceutical compositions of dexlansoprazole
WO2012001705A2 (en) 2010-06-29 2012-01-05 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
WO2012074110A1 (ja) 2010-12-03 2012-06-07 武田薬品工業株式会社 口腔内崩壊錠
KR20140007364A (ko) 2010-12-27 2014-01-17 다케다 야쿠힌 고교 가부시키가이샤 구강내 붕괴정
EP2663306A4 (en) * 2011-01-12 2014-01-01 Hetero Research Foundation POLYMORPHS OF DEXLANSOPRAZOLE SALTS
WO2012104805A1 (en) 2011-02-01 2012-08-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
WO2012111024A1 (en) 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Pharmaceutical compositions of dexlansoprazole
CA2840309A1 (en) * 2011-06-21 2012-12-27 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CN102875532B (zh) * 2011-07-15 2015-05-13 上海睿智化学研究有限公司 一种(r)-兰索拉唑异丙胺盐及其晶型和制备方法
CN102875530A (zh) * 2011-07-15 2013-01-16 上海睿智化学研究有限公司 一种(r)-兰索拉唑叔丁胺盐及其晶型和制备方法
CN102875531B (zh) * 2011-07-15 2015-08-19 上海睿智化学研究有限公司 一种(r)-兰索拉唑无水晶型及其制备方法
CN102234265B (zh) * 2011-08-08 2013-11-20 天津市汉康医药生物技术有限公司 兰索拉唑化合物
ES2561098T3 (es) 2011-11-30 2016-02-24 Takeda Pharmaceutical Company Limited Comprimido recubierto en seco
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2013179194A1 (en) 2012-05-31 2013-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline dexlansoprazole
CN103709139B (zh) * 2012-10-09 2016-12-21 上海汇伦生命科技有限公司 无水右兰索拉唑的制备方法
CN104177333A (zh) * 2013-05-24 2014-12-03 四川海思科制药有限公司 一种理化性质稳定的(r)-2-[[[3-甲基-4-(2,2,2-三氟乙氧基)-2-吡啶基]甲基]亚磺酰基]-1h-苯并咪唑
CN104650035A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 右兰索拉唑倍半水合物化合物
CN103664889B (zh) * 2013-12-19 2014-11-19 悦康药业集团有限公司 一种兰索拉唑化合物
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
CN104844576B (zh) * 2015-04-28 2017-03-08 山东罗欣药业集团股份有限公司 一种兰索拉唑或右旋兰索拉唑晶型化合物及其制备方法
CN104829594A (zh) * 2015-05-15 2015-08-12 苗怡文 一种治疗胃溃疡的药物兰索拉唑化合物
CN105017218A (zh) * 2015-07-01 2015-11-04 合肥安德生制药有限公司 一种右兰索拉唑晶型及其制备方法
CN104958276A (zh) * 2015-07-30 2015-10-07 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物兰索拉唑组合物胶囊
CN104997738A (zh) * 2015-08-10 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃病的药物兰索拉唑组合物干混悬剂
CN105399728B (zh) * 2015-12-20 2017-11-28 寿光富康制药有限公司 一种适用于工业化生产的右兰索拉唑的处理方法
CN108164507A (zh) * 2016-12-07 2018-06-15 天津药物研究院有限公司 一种右兰索拉唑单晶及其制备方法和用途
TR201701461A2 (tr) 2017-01-31 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dekslansoprazolün Enterik Kaplı Farmasötik Kompozisyonları
CN106866630B (zh) * 2017-04-01 2018-08-07 上海华源医药科技发展有限公司 一种右兰索拉唑的制备方法
CN107011329A (zh) * 2017-05-05 2017-08-04 广州大光制药有限公司 兰索拉唑一水合物晶型及其结晶制备方法
CN108794450B (zh) * 2018-07-24 2022-08-19 浙江恒康药业股份有限公司 制备无定型右旋兰索拉唑的方法
EP4598528A1 (en) 2022-10-04 2025-08-13 Arsenil Zabirnyk Inhibition of aortic valve calcification

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6043263A (en) 1996-11-12 2000-03-28 Byk Gulden Lomberg Chemische Fabrik Gmbh (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
EP0941102A1 (en) * 1996-11-22 1999-09-15 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth and nsaid
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
CA2320963A1 (en) 1998-01-30 1999-08-05 Sepracor, Inc. R-lansoprazole compositions and methods
EP1056457A4 (en) 1998-01-30 2006-10-25 Sepracor Inc S-LANSOPRAZOLE COMPOSITIONS AND METHODS OF USE
AU3596199A (en) * 1998-05-06 1999-11-23 Kobenhavns Universitet Treatment of celiac disease
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
WO2001002389A1 (fr) * 1999-06-30 2001-01-11 Takeda Chemical Industries, Ltd. Cristaux de composes benzimidazole
CN1117747C (zh) * 2000-06-19 2003-08-13 中国科学院成都有机化学研究所 光学纯兰索拉唑的制备方法
EP2596792A1 (en) * 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Stable solid preparations
CA2516600C (en) * 2003-03-24 2011-04-05 Eisai Co., Ltd. Process for production of sulfoxide proton pump inhibitors in the amorphous state
WO2006069159A2 (en) * 2004-12-20 2006-06-29 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising amorphous benzimidazole compounds
WO2006067599A2 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
NZ593629A (en) * 2007-12-18 2012-11-30 Watson Pharma Private Ltd Stable amorphous R-lansoprazole prepared by optically resolving racemic lansoprazole

Also Published As

Publication number Publication date
US9145389B2 (en) 2015-09-29
US7569697B2 (en) 2009-08-04
PT1129088E (pt) 2008-05-05
US20030045724A1 (en) 2003-03-06
ATE391126T1 (de) 2008-04-15
BRPI0011674B8 (pt) 2021-05-25
US8884019B2 (en) 2014-11-11
TWI275587B (en) 2007-03-11
NO20016087D0 (no) 2001-12-13
US6664276B2 (en) 2003-12-16
HK1123985A1 (en) 2009-07-03
CA2375201A1 (en) 2000-12-28
EP1977751A1 (en) 2008-10-08
US7737282B2 (en) 2010-06-15
AR079473A2 (es) 2012-01-25
EP1977751B1 (en) 2013-07-24
ES2426985T3 (es) 2013-10-28
TWI289557B (en) 2007-11-11
CY1114485T1 (el) 2017-01-25
CY1110384T1 (el) 2015-04-29
AR103295A2 (es) 2017-05-03
AR093609A2 (es) 2015-06-10
NO321168B1 (no) 2006-03-27
WO2000078745A3 (en) 2001-07-05
ES2300265T3 (es) 2008-06-16
HUP0201659A2 (hu) 2002-11-28
WO2000078745A2 (en) 2000-12-28
SI1129088T1 (sl) 2008-08-31
US20140012006A1 (en) 2014-01-09
PL352193A1 (en) 2003-08-11
HU229067B1 (en) 2013-07-29
KR20010071354A (ko) 2001-07-28
KR100407847B1 (ko) 2003-12-01
US20120316344A1 (en) 2012-12-13
US20040048898A1 (en) 2004-03-11
KR100537029B1 (ko) 2005-12-16
EP1129088B1 (en) 2008-04-02
AU778820B2 (en) 2004-12-23
AR100473A2 (es) 2016-10-12
US20080132547A1 (en) 2008-06-05
BR0011674A (pt) 2002-03-19
AR031069A1 (es) 2003-09-10
PT1977751E (pt) 2013-08-01
BE2014C017I2 (forum.php) 2019-05-21
DE60038481T2 (de) 2009-04-09
IL145996A0 (en) 2002-07-25
DE60038481D1 (de) 2008-05-15
CA2375201C (en) 2010-02-09
US8030333B2 (en) 2011-10-04
CN1355798A (zh) 2002-06-26
MXPA01012642A (es) 2002-07-22
US20100222391A1 (en) 2010-09-02
KR20030068592A (ko) 2003-08-21
EP1129088A2 (en) 2001-09-05
NO20016087L (no) 2001-12-13
DK1977751T3 (da) 2013-09-02
US8552198B2 (en) 2013-10-08
EP2343289A1 (en) 2011-07-13
ZA200108331B (en) 2002-10-10
HK1038227A1 (en) 2002-03-08
PL201068B1 (pl) 2009-03-31
CN1150186C (zh) 2004-05-19
US6939971B2 (en) 2005-09-06
US20090163553A1 (en) 2009-06-25
US7339064B2 (en) 2008-03-04
US20150025115A1 (en) 2015-01-22
US20110319450A1 (en) 2011-12-29
KR100514204B1 (ko) 2005-09-13
US20050228026A1 (en) 2005-10-13
AU5247800A (en) 2001-01-09
HUP0201659A3 (en) 2003-11-28
KR20010052467A (ko) 2001-06-25
BRPI0011674B1 (pt) 2017-05-30
NZ515702A (en) 2003-07-25
IL145996A (en) 2008-07-08
WO2004083200A1 (en) 2004-09-30
DK1129088T3 (da) 2008-06-09
US6462058B1 (en) 2002-10-08

Similar Documents

Publication Publication Date Title
MY125399A (en) Benzimidazole compound crystal.
AU5705700A (en) Crystals of benzimidazole compounds
BR9508292A (pt) Processos para a sintese enãncio-seletiva de um composto,(-)-5-metóxi-2[[(4-metóxi-3,5-dimetil-2-piridinil) metil]sulfinil]-1h-benzimidazol,(+)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h-benzimidazol,(+)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h benzimidazol composto e uso dos compostos
SE9900274D0 (sv) New compound
WO1998054171A8 (en) Novel form of s-omeprazole
CA2284470A1 (en) New crystalline form of omeprazole
MY111737A (en) Use of omeprazole as an antimicrobial agent.
UA32524C2 (uk) Спосіб одержання омепразолу
DK1177187T3 (da) Diarylsyrederivater som PPAR-receptorligander
EP1186602A3 (en) Omeprazole sodium salt and its use as anti-ulcer agent
ZA989999B (en) New process for the preparation of 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)1H-benzimidazole
EG23175A (en) New procedure for obtaining derivatives of 2-(2-(pyridinylmethylsulphinyl)-1H-benzimidazole)
BR0015220A (pt) Procedimento melhorado para a preparação de derivados de benzimidazol adequados como fármacos antiulcerosos, principalmente omeprazol ou pantoprazol
SE9404192D0 (sv) New process
KR100463031B1 (ko) 5-메톡시-2-[3,5-디메틸-4-메톡시피리딜메틸)설피닐]-1h-벤즈이미다졸의신규제조방법
ECSP003736A (es) Procedimiento mejorado para la preparacion de derivados de bencimidazol adecuados como farmacos antiulcerosos, particularmente omeprazol o pantoprazol
UY26420A1 (es) Procedimiento mejorado para la preparación de derivados bencimidazol adecuados como fármacos antiulcerosos, particularmente omeprazol o pantoprazol
MY118724A (en) New crystalline form of omeprazole
YU32301A (sh) Novi kristalni oblik omeprazola